Botulinum toxin A to decrease spasticity after stroke
References
1. Kerstens HCJW, Satink T, Nijkrake MJ, De Swart BJM, Nijhuis-van der Sanden MWG, Van der Wees, et al. Experienced consequences of spasticity and effects of botulinum toxin injections: a qualitative study amongst patients with disabling spasticity after stroke. Disabil Rehabil. [internet] 2020 [citado 20 Abril 2020]; 7: 1-8. Disponible en: http://www.dx.doi.org/10.1080/09638288.2020.1746843
2. Wissel J, Fheodoroff K, Hoonhorst M, Müngersdorf M, Gallien P, Meier N, et al. Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of Treatment. Front Neurol. [internet] 2020 [citado 20 Abril 2020]; 11: 104. http://www.dx.doi.org/10.3389/fneur.2020.00104
3. Abo M, Shigematsu T, Hara H, Matsuda Y, Nimura A, Yamashita Y, et al. Efficacy and Safety of OnabotulinumtoxinA 400 Units in Patients with Post-Stroke Upper Limb Spasticity: Final Report of a Randomized, Double-Blind, Placebo-Controlled Trial with an Open-Label Extension Phase. Toxins (Basel). [internet] 2020 [citado 20 Abril 2020]; 12(2): e127. http://www.dx.doi.org/10.3390/toxins12020127
4. Lazzaro C, Baricich A, Picelli A, Caglioni PM, Ratti M, Santamato A. AbobotulinumtoxinA and rehabilitation vs rehabilitation alone in post-stroke spasticity: A cost-utility analysis. J Rehabil Med. [internet] 2020 [citado 20 Abril 2020]; 52(2). pii: jrm00016. http://www.dx.doi.org/10.2340/16501977-2636
5. López de Munain L, Valls-Solé J, Garcia Pascual I, Maisonobe P. Botulinum Toxin Type A Improves Function According to Goal Attainment in Adults with Poststroke Lower Limb Spasticity in Real Life Practice. Eur Neurol. [internet] 2019 [citado 20 Abril 2020]; 82(1-3): 1-8. http://www.dx.doi.org/10.1159/000503172
2. Wissel J, Fheodoroff K, Hoonhorst M, Müngersdorf M, Gallien P, Meier N, et al. Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of Treatment. Front Neurol. [internet] 2020 [citado 20 Abril 2020]; 11: 104. http://www.dx.doi.org/10.3389/fneur.2020.00104
3. Abo M, Shigematsu T, Hara H, Matsuda Y, Nimura A, Yamashita Y, et al. Efficacy and Safety of OnabotulinumtoxinA 400 Units in Patients with Post-Stroke Upper Limb Spasticity: Final Report of a Randomized, Double-Blind, Placebo-Controlled Trial with an Open-Label Extension Phase. Toxins (Basel). [internet] 2020 [citado 20 Abril 2020]; 12(2): e127. http://www.dx.doi.org/10.3390/toxins12020127
4. Lazzaro C, Baricich A, Picelli A, Caglioni PM, Ratti M, Santamato A. AbobotulinumtoxinA and rehabilitation vs rehabilitation alone in post-stroke spasticity: A cost-utility analysis. J Rehabil Med. [internet] 2020 [citado 20 Abril 2020]; 52(2). pii: jrm00016. http://www.dx.doi.org/10.2340/16501977-2636
5. López de Munain L, Valls-Solé J, Garcia Pascual I, Maisonobe P. Botulinum Toxin Type A Improves Function According to Goal Attainment in Adults with Poststroke Lower Limb Spasticity in Real Life Practice. Eur Neurol. [internet] 2019 [citado 20 Abril 2020]; 82(1-3): 1-8. http://www.dx.doi.org/10.1159/000503172
Downloads
Published
2020-07-12
How to Cite
1.
Martínez Pizarro S. Botulinum toxin A to decrease spasticity after stroke. Rev 16 de abril [Internet]. 2020 Jul. 12 [cited 2024 Dec. 12];59(278):e914. Available from: https://rev16deabril.sld.cu/index.php/16_04/article/view/914
Issue
Section
Letter to the Editor
License
Those authors who have publications with this journal, accept the following terms:
The authors will retain their copyright and guarantee the journal the right of first publication of your work, which will be under a Creative license Commons Attribution-NonCommercial-ShareAlike 4.0 International . (CC BY-NC-SA 4.0).
The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (eg:deposit it in an institutional telemat
